Journal
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Volume 37, Issue 9, Pages 1765-+Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/ATVBAHA.117.309384
Keywords
cardiovascular disease; coronary artery disease; heart failure; hypertension; myocardial infarction
Categories
Funding
- Extramural Grant Program by Satellite Healthcare
- National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant [1R01DK108803]
- NIH/NIDDK [1R01DK108803, 1R21DK112087, 1R01DK103574, M01 RR-00080, M01 RR-00071, M0100032, P20-RRl1145, M01 RR00827, M01 RR00052, 2P20 RR11104, RR029887, DK 2818-02, DK057867, DK048689]
- National Cancer Institute, National Institutes of Health [HHSN26120080001E]
- Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research
- King Pharmaceuticals
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Forest Laboratories
- Pharmacia
- Upjohn
Ask authors/readers for more resources
Objective-Among African Americans, the apolipoprotein L1 (APOL1) risk variants have been associated with various types of kidney disease and chronic kidney disease progression. We aimed to determine whether these same risk variants also confer an increased risk for cardiovascular disease. Approach and Results-In a cohort of African Americans with hypertension-attributed chronic kidney disease followed for up to 12 years, we used Cox proportional hazards models to estimate the relative hazard of a composite cardiovascular disease outcome (cardiovascular death or hospitalization for myocardial infarction, cardiac revascularization procedure, heart failure, or stroke) for the APOL1 high-(2 risk variants) versus low-risk (0-1 risk variant) genotypes. We adjusted for age, sex, ancestry, smoking, heart disease history, body mass index, cholesterol, randomized treatment groups, and baseline and longitudinal estimated glomerular filtration rate, systolic blood pressure, and proteinuria. Among 693 participants with APOL1 genotyping. available (23% high risk), the high-risk group had lower mean estimated glomerular filtration rate (44.7 versus 50.1 mL/min per 1.73 m(2)) and greater proteinuria (median 0.19 versus 0.06) compared with the low-risk group at baseline. There was no significant association between APOL1 genotypes and the composite cardiovascular disease outcome in both unadjusted (hazard ratio= 1. 23; 95% confidence interval: 0.83-1.81) and fully adjusted (hazard ratio= 1. 16; 95% confidence interval: 0.77-1.76) models; however, in using an additive model, APOL1 high-risk variants were associated with increased cardiovascular mortality. Conclusions-Among African Americans with hypertension-attributed chronic kidney disease, APOL1 risk variants were not associated with an overall risk for cardiovascular disease although some signals for cardiovascular mortality were noted. Visual Overview-An online visual overview is available for this article.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available